Clinical Trial Update: A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease [Phase 2]

View source ↗

Summary

A Phase II study of MDX-060 in patients with relapsed or refractory Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• MDX-060

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hodgkin's Disease | Phase 2 | Status: COMPLETED